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ABSTRACT
ETS family transcription factors play major roles in prostate tumorigenesis with 
some acting as oncogenes and others as tumor suppressors. ETS factors can compete 
for binding at some cis-regulatory sequences, but display specific binding at others. 
Therefore, changes in expression of ETS family members during tumorigenesis can 
have complex, multimodal effects. Here we show that ELF1 was the most commonly 
down-regulated ETS factor in primary prostate tumors, and expression decreased 
further in metastatic disease. Genome-wide mapping in cell lines indicated that 
ELF1 has two distinct tumor suppressive roles mediated by distinct cis-regulatory 
sequences. First, ELF1 inhibited cell migration and epithelial-mesenchymal transition 
by interfering with oncogenic ETS functions at ETS/AP-1 cis-regulatory motifs. Second, 
ELF1 uniquely targeted and activated genes that promote senescence. Furthermore, 
knockdown of ELF1 increased docetaxel resistance, indicating that the genomic 
deletions found in metastatic prostate tumors may promote therapeutic resistance 
through loss of both RB1 and ELF1.
BACKGROUND
More than half of prostate tumors have a 
chromosomal rearrangement that results in aberrant 
expression of an ETS transcription factor that is not 
normally expressed in prostate cells. The most common 
of these rearrangements is the fusion of the ETS family 
member ERG to the promoter and 5’ UTR of the TMPRSS2 
gene, occurring in approximately 50% of prostate tumors. 
Other commonly rearranged ETS family members include 
ETV1, and ETV4 [1, 2]. These ETS factors, when coupled 
with additional oncogenic mutations, drive prostate 
tumorigenesis [3-5]. However, there are many other ETS 
factors expressed in normal prostate epithelia, and some of 
these can act as tumor suppressors. The tumor suppressive 
mechanisms of these normally expressed ETS factors and 
their interplay with oncogenic ETS factors are not well 
understood.
Because ETS factors bind to similar DNA sequences 
[6], there is the possibility of binding site competition 
between oncogenic ETS factors and ETS factors expressed 
in normal prostate cells. There are approximately 14 
members of the ETS family which are normally expressed 
within the prostate [7]. EHF and SPDEF are the two most 
highly expressed ETS factors in normal prostate, and 
both are reported as being down-regulated in prostate 
tumors, resulting in increased epithelial to mesenchymal 
transition (EMT), cell migration, and invasion [8-12]. 
These are similar phenotypes to those that occur when 
oncogenic ETS factors are expressed in prostate epithelial 
cells [13-15], and chromatin immunoprecipitation analysis 
indicates that EHF can compete with ERG for occupancy 
of the EZH2 and NKX3.1 promoters [16]. Inactivating 
point mutations and deletions of the ETS factor ERF were 
recently identified in about 4% of prostate tumors, and 
these mutations are able to recapitulate phenotypes of ERG 
overexpression; furthermore, ChIP-seq analyses indicate 
that ERF and ERG compete for binding throughout the 
genome [17]. Additional ETS factors have been shown 
to have tumor suppressive functions in the prostate. The 
interstitial deletion that most commonly results in the 
TMPRSS2/ERG fusion deletes one copy of the ETS gene 
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ETS2. The loss of ETS2 from this deletion, is associated 
with poor patient outcomes and promotes prostate cancer 
progression in a mouse model [18]. 
Evidence from Ewing’s sarcoma further supports 
the idea that binding site competition between ETS factors 
could contribute to tumorigenesis. In this type of sarcoma, 
85% of patients have a chromosomal translocation that 
results in the fusion of the EWSR1 gene with the ETS 
factor FLI1 [19]. We have recently reported that EWSR1-
FLI1 and the oncogenic ETS expressed in prostate cancer 
bind to similar cis-regulatory sequences and activate 
transcription through overlapping mechanisms [20]. It has 
been reported that transcriptional repression mediated by 
EWS-FLI1 can occur due to binding site competition and 
displacement of the endogenously expressed ETS protein 
ELF1 [21]. ELF1 is also normally expressed within 
the prostate, but its function in this tissue has not been 
characterized. 
ELF1 is a ubiquitously expressed ETS gene. 
Previous studies on ELF1’s function in cancer indicate 
both oncogenic and tumor suppressive roles. Studies in 
endometrial carcinoma, epithelial ovarian carcinoma, and 
non-small cell lung carcinoma show that ELF1 expression 
is positively correlated with histological grading and 
clinical outcome, indicating oncogenic function [22-
25]. ELF1 has also been shown to be required for the 
proliferation of cervical cancer cells infected with the 
HPV virus [26, 27]. In contrast to these oncogenic roles, 
ELF1 nuclear expression is negatively correlated with 
histological grading and tumor size in breast ductal 
carcinomas [28]. In various epithelial tumors ELF1, and 
related ETS factors ELF2 and ELF4, inhibit proliferation 
and undergo mutually exclusive mutations or deletions 
[29]. ELF1 has also been implicated as a potential tumor 
suppressor in prostate cancer through analyses of mRNA 
and DNA copy number alterations from patient samples 
[30]. 
Recent findings indicate that metastatic prostate 
tumors develop resistance to therapies by inactivating the 
tumor suppressor genes TP53 and RB1 [31, 32]. In patient 
tumors, inactivation most commonly occurs through point 
mutation of TP53 and genomic deletion of RB1 [33, 34]. 
Interestingly, the ELF1 gene is located 8 mb from RB1 
on chromosome 13 and can be co-deleted in metastatic 
prostate tumors. However, the contribution of ELF1 
deletion to prostate cancer has not been investigated.
This study investigates the role of ELF1 in prostate 
cancer, providing the first analysis of ELF1’s function 
within the prostate. ELF1 was the most commonly down-
regulated ETS factor in prostate tumors and even displayed 
significant down-regulation in tumors lacking genomic 
deletions. Using a variety of phenotypic assays and next 
generation sequencing experiments we determined that 
ELF1 represses cell migration through target genes with 
ETS/AP-1 cis-regulatory sequences, consistent with a 
model of binding site competition with oncogenic ETS 
factors. While ELF1 functioned as a repressor relative 
to the oncogenic ETS factors at cell migration genes, it 
bound to a unique set of cis-regulatory sequences where it 
functioned as an activator of genes promoting senescence. 
Furthermore, knockdown of ELF1 increased resistance 
to docetaxel, a common therapeutic for late-stage 
prostate cancer. These data indicate that decreased ELF1 
levels in prostate tumors provide a mechanism to evade 
chemotherapy-induced cellular senescence or cell death, 
allowing for cancer recurrence. 
RESULTS
ELF1 is negatively correlated with prostate cancer 
progression
In prostate cancer, three members of the ETS family 
(ERG, ETV1, and ETV4) are commonly overexpressed due 
to chromosomal translocations. A fourth member, ETV5 
is over-expressed in rare cases, and has been suggested 
to also be an oncogenic family member [15, 20]. In 
contrast, some normally expressed ETS family members 
are reported to be down-regulated in prostate tumors. To 
better understand the changes that might be occurring 
within the ETS family during prostate tumorigenesis, we 
compared the mRNA expression of 498 prostate tumors 
against 52 normal adjacent samples using the TCGA 
Prostate Adenocarcinoma dataset (Figure 1A) [http://
cancergenome.nih.gov/.]. As expected, the oncogenic 
ETS factors were overexpressed in a mutually exclusive 
pattern in approximately 50% of prostate tumors. One 
unexpected finding from this data was the widespread 
decrease in mRNA levels for ELF1 in tumors (Figure 
1A). A direct comparison of 52 prostate tumors with 
their matched adjacent normal showed that 43 out of 52 
samples have decreased ELF1 levels (Figure 1B). ELF1 
is the fourth highest expressed ETS mRNA in normal 
prostate cells and the decreased expression in prostate 
tumors is among the most significant in the ETS family 
(Supplemental Figure 1). Analysis of ELF1 expression 
from a separate dataset, which included castrate resistant 
metastatic samples, showed that ELF1 levels are decreased 
in primary tumors, and are dramatically decreased in 
metastatic samples (Figure 1C) [39]. These results suggest 
that ELF1 expression is negatively correlated with prostate 
cancer progression. 
To better understand the possible cause of the drastic 
mRNA decrease, copy number alterations and mutations 
were analyzed within the TCGA dataset. ELF1 possesses 
relatively few mutations within this prostate cancer dataset 
(0.2% samples with ELF1 mutation); however, prostate 
tumors have a high rate of ELF1 deletions (~15% deep 
deletion and ~27% shallow deletion). We noted that the 
ELF1 gene is located 8 mb from RB1, which is known 
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Figure 1: ELF1 is the most commonly downregulated ETS factor in prostate cancer. A. Heatmap representation of mRNA 
expression of the ETS family in 498 prostate cancer samples relative to the background distribution of expression from 52 normal prostate 
samples. The values displayed represent the individual Z-score for each normalized read count as compared to the normal prostate 
background distribution. B. Boxplot representation of ELF1 normalized read counts in 52 normal prostate samples (Blue) paired with 
matched tumor samples (Red) (p-value <0.001, paired t-test). C. Column graph of log2 (median-centered ratio) expression of ELF1 in a 
microarray experiment comparing normal prostate samples with benign, primary, and metastatic prostate samples [39]. D. Table detailing 
the copy number alterations in ELF1 and RB1 from the TCGA data set using GISTIC 2.0. E. Boxplot representation of ELF1 normalized 
read counts in 52 normal prostate samples (Blue) compared with ELF1 expression of all prostate cancer samples that have a normal ELF1 
copy number (Red) (p-value < 0.001, Welch Two Sample t-test). F. A boxplot representation of ELF1 levels in TCGA prostate tumors that 
are classified based on biochemical recurrence. P-values (* <0.05, ** < 0.01, *** < 0.001) are calculated with the Welch Two Sample t-test. 
G. RPKM expression values for ELF1 in the indicated prostate cell lines were obtained from Prensner et al. [38]. H. Immunoblot with the 
indicated antibodies (left) in a subset of the prostate cancer cell lines. Tubulin serves as a loading control.
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to be deleted in some late stage prostate tumors [31, 33, 
34, 39], and from this dataset we see that ELF1 is often 
co-deleted with RB1 (Figure 1D). To test whether loss of 
ELF1 simply represents a passenger effect of RB1 deletion 
we analyzed ELF1 expression from tumors with two 
copies of the ELF1 gene. These normal ELF1 copy number 
tumors still have significantly lower ELF1 expression 
(p-val <0.0001, Welch Two Sample T-Test) than adjacent 
normal tissue (Figure 1E). This result predicts additional 
mechanisms outside of genomic deletions which result 
in lower ELF1 levels, indicating selective pressure for 
this loss during tumor progression. Furthermore, prostate 
cancer patients with recurrent tumors have decreased 
ELF1 levels, indicating that ELF1 loss could contribute to 
prostate cancer progression (Figure 1F). 
To confirm that prostate cell line models recapitulate 
a similar difference in ELF1 expression between 
normal prostate and prostate cancer, mRNA and protein 
expression of ELF1 were compared across prostate cell 
lines. Analysis of previously published RNA-seq data 
[38] indicates that ELF1 mRNA levels are highest in 
normal prostate epithelial cells (PrEC) and immortalized-
normal prostate epithelial cells (RWPE-1) as compared 
to six prostate cancer cell lines (Figure 1G). Further, 
immunoblots indicate that PrEC cells have much higher 
ELF1 protein levels than prostate cancer cell lines (Figure 
1H). 
ELF1 is a negative regulator of migration and 
clonogenic survival in the presence of oncogenic 
ETS factors
ETS factors can regulate a wide-variety of cancer 
related phenotypes within prostate epithelial cells, but 
cell migration has been extensively used as a proxy 
to determine oncogenic or tumor suppressive activity 
[15, 20, 36]. To simulate the decreased expression of 
ELF1 within tumors, cell migration assays with ELF1 
knockdowns were performed in two different prostate cell 
lines; the immortalized, normal prostate epithelial cell 
line, RWPE-1, and the metastatic prostate cancer cell line, 
PC3 (Figure 2A). While there was no significant change 
in cell migration within the RWPE-1 cell line, there was 
a significant increase in cell migration in PC3 cells upon 
ELF1 knockdown. One major difference between these 
two cell lines is the overexpression of an oncogenic 
ETS factor, ETV4, within PC3 cells [7]. To determine if 
the presence of an oncogenic ETS factor affects ELF1’s 
ability to suppress cell migration, ERG was expressed in 
RWPE-1 cells and migration assays were repeated (Figure 
2A). ERG expression increased RWPE-1 cell migration 
(Figure 2A, third panel) and in this cellular background 
ELF1 repressed cell migration (Figure 2A, fourth panel). 
To confirm these results, scratch assays were performed 
under the same conditions and the trends matched the 
transwell assays (Figure 2B). These data indicate that 
ELF1 has the ability to repress prostate cell migration in 
the presence of oncogenic ETS factors.
Epithelial to mesenchymal transition (EMT) is 
characterized by epithelial cells losing polarity and 
Table 1: ELF1 binds housekeeping gene promoters and tissue specific enhancers
Most overrepresented pathways (Promoters) p value
Gene Expression 8.7x10-25 
rRNA Processing 6.7x10-7
Nonsense-Mediated Decay (NMD) 6.7x10-7
rRNA Processing in the Nucleus and Cytosol 6.7x10-7
Processing of Capped Intron-Containing-Pre-mRNA 3.1x10-6
Ribosome – Homo sapiens (human) 3.9x10-6
SRP-Dependent Cotranslational Protein Targeting To Membrane 4.3x10-6
Cytoplamsic Ribosomal Proteins 6.9x10-6
Most overrepresented pathways (Enhancers) p value
IL-7 3.7x10-5
Notch Signaling Pathway 0.00020
Ras Signaling Pathway – Homo sapiens (human) 0.00020
Fc-epsilon Receptor I Signaling in Mast Cells 0.00023
G1 to S Cell Cycle Control 0.00052
IL5 0.00055
IL2 Signaling Events Mediated by STAT5 0.00057
Adherens Junctions Interactions 0.00071
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Figure 2: ELF1 represses oncogenic ETS mediated phenotypes in prostate cells. A. Boxplot representation of transwell 
migration of RWPE-1, PC3, and RWPE-ERG cells expressing a shRNA targeting ELF1 (shELF1), or negative control shRNA targeting 
luciferase (shLuc) and/or expressing exogenous ERG or empty vector control. B. Boxplot representation of scratch assays measured as a 
decrease in the wound area in RWPE-1 and PC3 cells with a shRNA control (shLuc) or ELF1 shRNA knockdown (shELF1), with or without 
ERG. C. Immunoblots with the indicated antibodies. Tubulin is a loading control. D. Expression of indicated mRNA in the indicated cell 
lines relative to cells expressing shLuc alone. Values shown as mean and SEM (n = 3). E. Boxplot representation of clonogenic survival 
assays of cells expressing shELF1 or shLuc in RWPE-1, PC3, and RWPE-ERG cells measured as the number of colonies. All P-values (* 
<0.05, ** < 0.01, *** < 0.001) were calculated with the Welch Two Sample t-test.
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becoming more migratory. To test ELF1 regulation 
of EMT, protein levels of an epithelial marker, CDH1 
(E-cadherin), and a mesenchymal marker, VIM (vimentin), 
were monitored in each condition (Figure 2C). ELF1 
knockdown did not alter CDH1 levels, but VIM increased 
upon ELF1 knockdown in RWPE-1 cells overexpressing 
ERG. Steady state mRNA levels of mesenchymal markers 
VIM and PAI1 were determined by qRT-PCR in RWPE-
1, RWPE-ERG, and PC3 cells, with and without ELF1 
knockdown (Figure 2D). These mesenchymal genes were 
expressed at higher levels upon ELF1 knockdown in cells 
expressing oncogenic ETS, indicating that ELF1 can 
repress the ability of oncogenic ETS to promote EMT.
Oncogenic ETS factors can increase the clonogenic 
survival capacity of prostate cells along with their 
migratory activity [20]. To determine if ELF1 has any 
effect on this phenotype we conducted clonogenic survival 
assays under the same conditions as the migration assays. 
Similar to the migration assays, ELF1 was able to repress 
clonogenic survival of RWPE-1 cells only in the presence 
of ERG (Figure 2E). These results suggest that ELF1 can 
inhibit multiple functions of oncogenic ETS factors.
ELF1 can bind the same ETS/AP-1 cis-regulatory 
elements as oncogenic ETS factors.
Given that ELF1 only repressed migration and 
clonogenic survival in the presence of an oncogenic ETS 
factor, it is possible that ELF1 competes for binding with 
oncogenic ETS factors and attenuates transcription due to 
weaker transactivation function. To test this hypothesis, 
chromatin immunoprecipitation coupled with next-
generation sequencing (ChIP-seq) was used to map ELF1 
genomic binding in RWPE-1 and PC3 cells and compared 
to a published ChIP-seq of ELF1 in DU145 prostate 
cancer cells [36]. ELF1 occupancy was similar between 
the cell lines (Figure 3A), however, the signal was highest 
in RWPE-1 cells, corresponding to the higher level of 
ELF1 in this cell line (Figure 1G). For this reason, the 
RWPE-1 cell line was selected for further analysis. 
Using a p-value cut-off of 1x10-5, 1837 binding sites 
were called for ELF1 in RWPE-1 cells using the MACS 
peak-caller. As expected, motif enrichment analysis for 
these called binding sites identified CCGGAAGT as 
the most overrepresented motif, matching the known 
DNA sequence preference of ELF1 and most of the ETS 
family (Figure 3B) [6]. Previous analyses of ETS factor 
binding patterns have identified high affinity ETS binding 
sequences in the promoters of many housekeeping genes 
that can non-specifically bind any ETS factor, while the 
binding sites associated with tissue specific functions of 
individual ETS factors occur mostly in enhancers [40, 
41]. We observed a similar pattern for ELF1 (Table 1), 
therefore we focused our analysis on ELF1 enhancer sites 
(>500 bp from TSS). 
To test if ELF1 binds the same enhancers as ERG, 
consistent with competition, we compared ELF1 binding 
to our previously published ChIP-seq of ERG in RWPE-
ERG cells [20]. A heatmap representation of the signal for 
each factor at called ELF1 sites demonstrated overlapping 
binding with ERG at about one-half of ELF1 targets, but 
also showed a subset of ELF1 sites with no evidence of 
ERG binding (Figure 3C). Using a 2-fold cutoff for the 
ratio of binding site signal to adjacent background signal 
for ERG, we determined that ELF1 has 853 binding sites 
that overlap with ERG (443 promoter and 410 enhancer) 
and 984 unique binding sites with limited or no ERG 
signal (135 promoter and 849 enhancer). Motif enrichment 
analysis of the enhancer regions for each category showed 
a unique set of binding motifs. In the overlapping enhancer 
binding regions there was an enrichment for ETS, AP-1, 
and SP1 binding sequences, while the unique ELF1 bound 
Table 2: ELF/ERG overlapping and ELF1 unique enhancers are near genes with distinct biological functions
Most overrepresented pathways (ELF/ERG overlapping Enhancers) p value
IL-5 Signaling Pathway 0.00047
Cell Junction Organization 0.00060
Signaling by FGFR1 0.00133
Cell-Cell Communication 0.00136
Leptin Signaling Pathway 0.00154
VEGFA-VEGFR2 Signaling Pathway 0.00182
Most overrepresented pathways (ELF1 Unique Enhancers) p value
Signaling by NOTCH 0.00051
G1 to S Cell Cycle Control 0.00076
Adherens Junctions Interactions 0.00077
Breast Cancer – Homo sapiens (human) 0.00089
Melanoma – Homo sapiens (human) 0.00105
Cyclin D Associated Events in G1 0.00266
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Figure 3: ELF1 can bind to two distinct sets of cis-regulatory sequences. A. Heatmap representation of the ChIP enrichment 
of ELF1 in RWPE-1, DU145, and PC3 cells, centered on all called ELF1 bound regions in RWPE-1 cells. Bound regions are indicated 
between the “5’ end” and “3’ end” indicators with an extended view that includes the surrounding 7 kb on either side of the bound region. 
The heatmaps were generated using NGSplot [50]. B. Three most enriched motifs at ELF1 binding sites in RWPE-1 cells as determined by 
RSAT peak-motifs algorithms C. Heatmap representation of the ChIP enrichment of ELF1 in RWPE-1 cells and ERG in RWPE-ERG cells, 
centered on all called ELF1 bound regions. Bound regions are indicated between the “5’ end” and “3’ end” indicators with an extended view 
that includes 7 kb on either side of the bound region. Heatmaps were generated by NGSplot [50]. D. Three most enriched motifs at ELF1 
bound enhancers (>500 bp from TSS) in two different categories, ELF1 enhancers that are bound by ERG and ELF1, and enhancers with 
only background ERG signal (ELF1 only). E. Relative luciferase reporter activity for two firefly luciferase reporter constructs (synthetic 
3xETS/AP-1 sites and a fragment of a FHL3 enhancer) in RWPE-ERG cells with ELF1 shRNA knockdowns F. Immunoblot with the 
indicated antibodies (left) in the same cell lines as (G). Tubulin serves as a loading control. G. Relative luciferase reporter activity for the 
3xETS/AP-1 firefly luciferase reporter constructs in PC3 cells with ELF1 shRNA or overexpression as indicated. Luciferase values are 
the ratio of firefly luciferase to minimal promoter controlled renilla luciferase signal, and this ratio was then normalized to shLuc control. 
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enhancers were enriched for GATA, ETS, and TFAP2C 
sequences (Figure 3D). Neighboring ETS and AP-1 
sites are enriched at cis-regulatory regions controlling 
genes associated with cell migration [36]. Pathway 
analysis of the genes nearest to ELF1/ERG overlapping 
sites did indeed show enrichment for migration related 
pathways, such as cell to cell communication, cell junction 
organization, and various growth factor and cytokine 
signaling pathways (Table 2). 
Combined with the migration assay results, 
these data indicated that ELF1 and ERG may compete 
for binding at ETS/AP-1 sites, with ERG acting as a 
transcriptional activator and ELF1 acting as a weaker 
activator or a repressor. To confirm ELF1’s repressive 
activity at ETS/AP-1 sites in cells expressing ERG, a 
luciferase assay was performed with two ETS/AP-1 
regulated reporter constructs (Figure 3E). The first was 
an artificial construct with three copies of the ETS/AP-1 
sequence upstream of a minimal reporter. The second has 
the ETS/AP-1 containing enhancer of the FHL3 gene, 
which we have previously used to test transcriptional 
activation by ERG [20, 35]. Knockdown of ELF1 in 
RWPE-ERG cells increased expression of both reporters. 
In PC3 cells, which overexpress ETV4, ELF1 knockdown 
Table 3: ELF1 represses genes associated with EMT and activates genes associated with cell cycle and senescence
Most overrepresented categories (Sig. ERG Act. & Sig ELF1 Rep.) Adj. p-value
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate 0.0155





Circulatory system development 0.0337
Stem cell development 0.0337
Modulation of excitatory postsynaptic potential 0.0337
Cell morphogenesis involved in neuron differentiation 0.0337
Anatomical structure formation involved in morphogenesis 0.0337
Axonogenesis 0.0337
Blood vessel development 0.0337
Positive regulation of excitatory postsynaptic potential 0.0337
Vascular endothelial growth factor receptor signaling pathway 0.0337
Most overrepresented categories (top 1000 Sig. ELF1 Activated) Adj. p-value
Meiotic recombination 0.0000767
SIRT1 negatively regulates rRNA Expression 0.0000767
DNA methylation 0.0000767
RNA Polymerase I Promoter Opening 0.0000767
DNA Damage/Telomere Stress Induced Senescence 0.0000767
PRC2 methylates histones and DNA 0.0000802
B-WICH complex positively regulates rRNA expression 0.0000849
Packaging Of Telomere Ends 0.0000849
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 0.0000849
Cellular Senescence 0.000179
Oxidative Stress Induced Senescence 0.000188
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription 0.000227
Condensation of Prophase Chromosomes 0.000227
Senescence-Associated Secretory Phenotype (SASP) 0.000227
Amyloid fiber formation 0.000258
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and overexpression cell lines were generated (Figure 3F). 
Similar to the RWPE-ERG cells lines, ELF1 knockdown 
increased the 3x ETS/AP-1 reporter, while ELF1 over-
expression decreased the reporter (Figure 3G). Therefore, 
ELF1 can repress ETS/AP-1 regulated reporters in 
oncogenic ETS-overexpressing cell lines.
Table 4: ELF1 expression in prostate tumors negatively correlates with prostate cancer and chemotherapy resistance 
genes
ELF1 Positively Correlated Gene Sets Size NES FDR q-val
LIU Prostate Cancer DN 466 2.91 <0.0001
KANG Doxorubicin Resistance DN 19 2.26 <0.0001
TOMLINS Prostate Cancer DN 40 2.22 <0.0001
ALONSO Metastasis DN 26 1.80   0.0034
WANG Tumor Invasiveness DN 208 1.60   0.0208
ELF1 Negatively Correlated Gene Sets Size NES FDR q-val
HONMA Docetaxel Resistance 34 -2.24 <0.0001
LIU Prostate Cancer UP 90 -2.22 <0.0001
RHODES Cancer Meta Signature 64 -1.90   0.0011
WANG Tumor Invasiveness UP 370 -1.79   0.0026
TOMLINS Prostate Cancer UP 40 -1.76   0.0035
Figure 4: ELF1 represses EMT, but activates cellular senescence. A. Gene Set Enrichment Analysis (GSEA) was used to 
compare RNA-seq of RWPE-ERG and RWPE-ERG shELF1 for the indicated gene sets from MSigDB Hallmarks or Reactome. The 
fpkm values were provided for the three biological replicates in each condition and the Signal2Noise ratio was used to rank genes. B. 
Immunoblot with the displayed antibodies (left) in PC3 cells with a control shRNA (shLuc) or ELF1 shRNA knockdown (shELF1), or a 
retroviral overexpression of ELF1 (ELF1 OvExp). C. Microscopic images PC3 cells from (B). Images were converted to grayscale and the 
saturation was adjusted to provide a clearer outline of the cells. The black arrows indicate cells that appear to be undergoing senescence. 
D. Quantification of β-galactosidase positive staining in PC3 cells expressing indicated constructs relative to shLuc (n = 3). P-values 
determined by one-way ANOVA with Tukey’s Test as the post-hoc analysis (* <0.05, ** < 0.01, *** <0.001).
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ELF1 represses EMT genes, but activates genes 
promoting cellular senescence
To better understand ELF1’s function in prostate 
epithelial cells we performed differential expression 
analysis using RNA sequencing of RWPE-1 cells, RWPE-
ERG cells, and RWPE-ERG cells with ELF1 knockdown. 
1880 genes were significantly downregulated and 2096 
genes were significantly upregulated upon knockdown 
of ELF1 in RWPE-ERG cells. Gene set enrichment 
analysis was performed on the changes in gene expression 
when ELF1 was depleted from RWPE-ERG cells. EMT 
hallmark genes were enriched within the ELF1 repressed 
category (Figure 4A). Furthermore, ontology analysis of 
the genes significantly activated by ERG and repressed 
by ELF1 showed enrichment for genes implicated in cell 
morphogenesis, mesenchyme development, and VEGF 
signaling (Table 3). These results matched the migration 
assays and qRT-PCR analysis from the RWPE-1 and PC3 
cell lines (Figure 2), where the oncogenic ETS drive EMT 
and migration while ELF1 opposes this function.
Looking in the opposite direction, ELF1 activated 
gene sets were enriched for categories related to cell 
cycle control, and cellular senescence (Figure 4A). 
ELF1 has previously been demonstrated to regulate cell 
proliferation in epithelial cells and thus identification 
of cell cycle pathways was expected [26, 29]; however, 
the abundance of senescence related pathways was an 
unexpected finding. Ontology analysis of the top 1000 
significantly activated genes by ELF1 from the RNA-seq 
also displayed a number of senescence related pathways 
(Table 3). Interestingly, when ELF1 was overexpressed in 
PC3 cells (Figure 3F), a number of cells took on a large, 
flattened, fried egg-like morphology, consistent with cells 
undergoing senescence (Figure 4B). To test if these cells 
were undergoing senescence, we tested for β-galactosidase 
activity, a common marker of senescence. There was a 
significant increase in β-galactosidase staining of PC3 
cells when ELF1 was overexpressed, and a slight decrease 
upon knockdown, demonstrating that over-expression of 
ELF1 activated senescence (Figure 4C). 
ELF1 loss results in increased resistance of 
prostate cancer cells to treatment
Gene set enrichment analysis of the TCGA prostate 
cancer dataset, ranked based on the Pearson correlation of 
each gene relative to ELF1 mRNA levels, provided further 
support that ELF1 can function as a tumor suppressor 
within the prostate (Table 4). Genes which positively 
correlated with ELF1 expression in prostate tumors were 
enriched for gene sets downregulated in prostate cancer, 
metastasis related pathways, and chemotherapy resistance; 
while genes that negatively correlated with ELF1 showed 
enrichment for gene sets upregulated in these same 
categories. While the prostate cancer and metastasis 
related gene sets were expected based on our previous 
genomic and phenotypic assay findings, the ability of 
ELF1 to potentially affect chemotherapy resistance was 
novel. It has been recently reported that RB1 deletion can 
promote resistance to chemotherapy in prostate cancer 
[31, 34]; however, as the ELF1 locus is often lost in these 
same genomic deletions, we asked if ELF1 depletion 
might contribute to chemotherapy resistance.
Figure 5: ELF1 sensitizes prostate cells to chemotherapy. A. Cell viability analysis of RWPE-1 or RWPE-ERG cells with a 
lentiviral luciferase knockdown (shLuc) or ELF1 knockdown (shELF1) (n = 3). B. Barplot representation of the Mean and SEM IC50 value 
for analysis in (A). IC50 values were calculated using a nonlinear fit of the log(inhibitor) vs. response - Variable slope (four parameters) 
in Prism. P-values were determined using a one-way ANOVA with Tukey’s Test as the post-hoc analysis (* <0.05, ** < 0.01, *** <0.001).
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To test if ELF1 loss might contribute to 
chemotherapy resistance, RWPE-1 cells, with or without 
ERG expression, were treated with docetaxel. We found 
that depletion of ELF1 in both conditions resulted in 
significantly increased IC50 values, indicative of a 
decreased sensitivity to docetaxel (Figure 5A). ELF1 
depletion increased the IC50 by 3.2-fold in RWPE-1 
cells, and 3.8-fold in RWPE-ERG cells (Figure 5B). These 
results further support the idea that ELF1 loss could result 
in increased resistance to prostate cancer treatments and 
correlate with the finding that ELF1 levels are lower in 
patients with recurrent tumors (Figure 1F).
DISCUSSION
Here we report that ELF1 can have tumor 
suppressive functions in prostate epithelial cells and 
that ELF1 levels are negatively correlated with cancer 
progression within this tissue. ELF1 binds to some of the 
same ETS binding sites as ERG, where ELF1 functions 
as a transcriptional repressor of cell migration genes; 
however, at sites where it binds uniquely, ELF1 activates 
and upregulates genes involved in senescence. Therapeutic 
strategies for invasive prostate cancer commonly include 
docetaxel treatment, which result in senescence or death 
of the cancer cells [42, 43]. ELF1 levels may be reduced 
in tumors to allow for the bypass of these pathways upon 
exposure to chemotherapies. This function, along with 
ELF1’s ability to repress cell migration at ETS/AP-1 sites, 
provides a potential mechanism for tumor suppressive 
functions of ELF1. 
Within prostate cancer, it has been well established 
that the oncogenic ETS factors, most often ERG, become 
overexpressed through chromosomal rearrangements 
and elicit several phenotypic changes that allow for 
the progression from a benign neoplasia to an invasive 
carcinoma, when paired with PTEN deletion [39, 44, 45]. 
However, the role of the endogenously expressed ETS 
factors within the prostate and their ability to compete 
with the oncogenic ETS factors has been much less 
studied. Several ETS family members have been shown 
to act as tumor suppressors within the prostate (EHF, 
SPDEF, ERF, etc) [8, 10, 12, 17, 46]. Of these, EHF and 
ERF have been shown to directly compete with oncogenic 
ETS at cis-regulatory sequences, opposing the ability of 
the oncogenic ETS to activate nearby genes [16, 17]. Here 
we find that the commonly downregulated ETS factor 
ELF1 can bind and repress the same ETS/AP-1 sequence 
elements that are activated by oncogenic ETS factors to 
induce EMT and cell migration. The downregulation of 
ELF1 in ETS fusion positive prostate tumors could allow 
for increased binding of oncogenic ETS factors at these 
sites, leading to a subsequent activation of genes involved 
in various cancerous phenotypes.
Previous cancer studies indicate that ELF1 can 
be a tumor suppressor or an oncogene, depending on 
the cell type [22-24, 26, 28]. The proposed oncogenic 
function of ELF1 stems from its ability to promote the 
cell cycle in a similar manner to E2F transcription factors. 
Like E2F factors, ELF1 binds hypophosphorylated RB1, 
and this represses ELF1 mediated transcription of cell 
cycle genes. However, hyperphosphorylation of RB1 
by cyclin dependent kinases leads to dissociation from 
ELF1 and allows ELF1 to activate transcription as cells 
pass through the cell cycle [47]. Therefore, RB1 status 
is a key to ELF1 function. This is evidenced in cervical 
cancer, where the presence of the human papilloma 
virus E7 protein inactivates RB1 and allows ELF1 to 
switch from a repressor of proliferation to an activator 
of proliferation [26]. Recent findings indicate that 
metastatic prostate tumors develop resistance to therapies 
by inactivating TP53 through point mutations and RB1 
through genomic deletion [31, 33, 34]. RB1 in other tumor 
types is highly mutated to produce nonfunctional protein 
products or to disrupt the E2F binding pocket; however, 
the aforementioned genomic deletions of RB1 are most 
prevalent within prostate cancer [39]. Interestingly, 
the ELF1 locus is roughly 8 Mb away from RB1 on 
chromosome 13 and is often co-deleted in prostate tumors 
(Figure 1D). Our findings that ELF1 promotes senescence 
in prostate cells could explain why RB1 is lost due to 
deletion, rather than mutation in prostate tumors. We 
hypothesize that ELF1 could act as a sensor of RB1 status 
in prostate cells. Mutational inactivation of RB1 would 
result in high transcriptional activity of ELF1 which 
would activate cellular senescence. However, the large 
chromosomal deletions found in prostate tumors delete 
both RB1 and ELF1, and this response would be lost.
Further evidence of ELF1 having the ability to 
regulate pathways involved in cell fate and cell cycle 
progression comes from an unbiased search for factors 
that are phosphorylated and experience changes in mRNA 
expression upon ionizing radiation in human embryonic 
kidney 293T cells and osteoscarcoma U2OS cells. ELF1 
was identified as a potential downstream target of the 
DNA damage response pathway, and following ionizing 
radiation U2OS cells with a siRNA against ELF1 were 
more likely to escape cell cycle arrest by bypassing the 
G2-M checkpoint [48]. Similarly, ELF4, a member of 
the same ETS subfamily as ELF1, was demonstrated to 
be a regulator of the DNA damage response and is used 
to recruit ATM to sites of DNA damage. In this context, 
persistent ELF4 blocked the repair of damaged DNA 
which led to increased apoptosis [49]. Thus the loss of 
ELF4 allowed for increased DNA damage repair and 
increased resistance to treatment, similar to ELF1 in this 
study. 
Our findings, along with previous studies of ELF1 
and its subfamily, suggest that ELF1 has the ability to 
compete with other expressed ETS factors and is also 
able to regulate cell fate decisions in prostate cancer 
cells. The loss of ELF1 through chromosomal deletion or 
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mRNA downregulation can contribute to prostate cancer 
progression by allowing for increased binding of stronger 
ETS transactivators at cell migration genes and by 
decreasing ELF1’s ability to activate cellular senescence 
or death upon treatment with chemotherapies.
MATERIALS AND METHODS
Cell culture and viral transduction
The PC3 and RWPE-1 cell lines were purchased 
from the American Type Culture Collection (ATCC) 
within a year of starting this study. The cell lines were 
frozen within 4 passages of obtaining them from ATCC to 
allow for consistent results. These cells were authenticated 
by viral testing (RWPE-1 cells), isoenzymes (RWPE-
1 cells), DNA profile, and cytogenetic analysis by the 
ATCC before purchase. Cell lines were cultured by ATCC 
recommendation as follows: EBNA293 and HEK-293T 
were grown in Dulbecco’s modification Eagle (Sigma) 
with 10% fetal bovine serum (Sigma). PC3 cells were 
grown in F12K (Sigma) with 10% FBS. RWPE-1 cells 
were grown in Keratinocyte media (ThermoFisher). All 
media included 1X Penicillin/Streptomycin (Mediatech-
Cellgro). 
The lentiviruses for the luciferase and ELF1 
shRNAs were produced by co-transfection of pLKO.1 




GTAAGTTTTTTTG, Luciferase Reverse Primer:AATT
CAAAAAAACTTACGCTGAGTACTTCGATCTCTT
GAAGTACTCAGCGTAAG, ELF1 Forward Primer:CC
GGAAACAGTGCCACTCACAACAGCTCGAGCTG
TTGTGAGTGGCACTGTTTTTTTTG, ELF1 Reverse 
Primer:AATTTCAAAAAAAACAGTGCCACTCACA
ACAGCTCGAGCTGTTGTGAGTGAGTGGCACTG 
TTT, in HEK293T cells with pMDLg/pRRE (Addgene 
plasmid 12251), pRSV-Rev (Addgene plasmid 12253) and 
pMD2.G (Addgene plasmid 12259) packaging plasmids 
as previously described [35]. Retroviral overexpression 
vectors for ELF1 and ERG were produced using the 
method previously described in [20].
RNA sequencing and analysis 
Total RNA for three independent biological 
replicates was isolated from RWPE-1 cells transduced with 
lentiviral shRNA knockdown or retroviral overexpression 
vectors (see above) using the RNeasy mini kit (Qiagen) 
according to manufacturer’s instructions. RNA was DNase 
treated with the RNAse-Free DNase kit (Qiagen) per the 
manufacturer’s protocol. The RNA was polyA selected 
using purified oligo(dT) beads (Invitrogen). Sequencing 
libraries were generated using the Illumina TruSeq sample 
preparation protocol. The sequencing reads were analyzed 
with the Tuxedo Suite RNA sequencing pipeline to obtain 
differential gene expression. Data files are available for 
download from NCBI’s Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/), accession number 
GSE113499.
Protein immunoblotting and RNA quantification
Total protein extract from equal number of cells 
was separated on 10% SDS-PAGE gels, transferred to 
nitrocellulose membrane (Bio-Rad), blocked in 5% milk 
in TBS (10mM Tris, pH8.0, 150 mM NaCl), incubated 
with primary and secondary antibodies, and visualized 
by ECL (Thermo Scientific) using standard procedures. 
Antibodies used in this study were ELF1 (sc-631, Santa 
Cruz Biotechnology), ERG (CM 421, Biocare), CDH1 
(610181, BD Transduction Laboratories), VIM (clone V9, 
M0725, Dako), and Tubulin (T9026, Sigma).
RNA levels were measured by reverse transcription 
followed by quantitative PCR with standard curves 
as described previously [15], using the following 
DNA oligonucleotides; 18S Forward Primer: 
GGTGAAATTCTTGGACCGGC, 18S Reverse Primer: 
GACTTTGGTTTCCCGGAAGC, VIM Forward Primer: 
CGCCATCAACACCGAGTTC, VIM Reverse Primer: 
ATCTTATTCTGCTGCTCCAGGAA, PAI1 Forward 
Primer: CCTAGAGAACCTGGGAATGACC, PAI1 
Reverse Primer: CCTCGATCTTCACTTTCTGCAGC. 
RNA levels were normalized to 18S rRNA.
Luciferase reporter assay
A 474bp fragment of an FHL3 enhancer 
(chr1:38465034-38465507, hg19) and a synthetic 3xETS/
AP-1 region (core binding sequence GGAAGTGACTCA) 
were cloned into the firefly luciferase reporter pGL4.25 
(Promega). The methods for generating these plasmids are 
described in [20] for the FHL3 enhancer and [35] for the 
3xETS/AP-1 plasmid. The dual luciferase reporter assay 
(Promega) measures luciferase activity as described [35]. 
Transwell migration assays
Transwell migration assays were carried out as 
previously described [15], with minor modifications. In 
brief, 5x104 cells were introduced to the transwell (8 µM 
pore size; BD Bioscience) and incubated for 48 hrs (PC3 
cells) or 64 hrs (RWPE-1 cells). Cells on the underside 
of the transwell were then fixed, stained, and counted. A 
mean count of five locations on the membrane determined 
the number of migrated cells per technical replicate, and 
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the average of 2 technical replicates was used to determine 
the number of migrated cells for each biological replicate. 
Scratch assays
Scratch assays were performed in 6 well plates with 
an initial count of 1x106 cells. Cells adhered for 24 hours 
before being scratched with a P1000 tip. Each biological 
replicate was the mean of three technical replicates on the 
same plate. After scratching, the media was removed and 
the plate was washed with PBS before fresh media was 
added. Images were taken at this time to quantify the size 
of the initial wound. The cells were then incubated for 
48 hrs (RWPE-1) or 24 hrs (PC3). The cells were then 
imaged at the same location. ImageJ quantified the size of 
each scratch. 
Chromatin immunoprecipitation and sequencing
ChIP was previously described [15]. Briefly, cells 
were crosslinked using 1% v/v formaldehyde (Fisher 
Scientific) for 15 minutes and quenched with 2M Glycine 
for 5 minutes. Isolated cells were lysed and sonicated 
(Daigenode, Bioruptor Pico) for 3 minutes (30 sec ON/
OFF). Nuclear lysate was rotated with antibody for 4 hours 
at 40C, washed, and DNA isolated by phenol/chloroform. 
Antibodies used were ERG (CM 421, Biocare), and ELF1 
(sc-631, Santa Cruz Biotechnology). Library preparation 
was carried out as previously described [36]. Peak calling 
was performed using Macs v1.4.2 and nearest neighboring 
genes were determined using the USeq platform (http://
useq.sourceforge.net/) with the hg19 genome. 
ChIP-seq Data files generated in this study can be 
found via Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/) accession number GSE113499.
Motif searching and ontology analysis 
Enriched motif searching used the RSAT “peak 
motifs” platform (http://rsat.sb-roscoff.fr/). Settings 
for RSAT are as followed: Discover over-represented 
words and discover words with local overrepresentation 
at an oligomer length of 6, 7, and 8. Number of motifs 
returned per algorithm was set equal to 5. All other options 
remained as default settings. Ontology and pathway 
searches used ConsensusPathDB (cpdb.molgen.mpg.
de) or gProfiler (https://biit.cs.ut.ee/gprofiler/). Settings 
for the ConsensusPathDB were default with a minimum 
overlap of 5 genes. gProfiler settings were default except 
for a functional categorize size maximum of 2000, no 
Hierarchical sorting, and only Biological process, KEGG, 
and Reactome were selected as options for searching.
Data curation and heatmaps
RNA-sequencing data from patient tumor and 
adjacent normal samples were generated in whole by the 
TCGA Research Network (http://cancergenome.nih.gov/.). 
Normalized read counts for each ETS family member 
were used to generate the Z-score heatmap. A background 
distribution of normalized read counts was created from 
the 52 adjacent normal samples and the Z-score was 
generated for each tumor sample by comparing the tumor 
normalized read count to the adjacent normal background 
distribution. The heatmap was clustered using the Ward 
method with correlation-based distance. FPKM-UQ values 
for the top 10 expressed ETS factors in prostate cells were 
pulled from the GDC TCGA Prostate Cancer (PRAD) data 
set on the Xena browser [37].
RNA-sequencing data for various prostate cancer 
cell lines was obtained from a publicly available data 
set on GEO (GSE31728) [38]. Only the single-end read 
samples were used from this data to ensure that all of 
the sequencing files were analyzed consistently. The 
sequencing reads were analyzed using the Tuxedo Suite 
RNA sequencing pipeline. 
Clonogenic survival assay
Approximately 1000 cells were seeded onto 6-well 
tissue culture plates and incubated at 37 °C for 9-14 days. 
Upon completion of the incubation period, cells were fixed 
with 10% formalin and were stained with 0.5% crystal 
violet in 25% methanol. Stained colonies were counted 
using the Genesys image acquisition and analysis software 
(Syngene). The number of colonies are reported as the 
mean of three biological replicates, each the average of 
two technical replicates. 
Senescence assay: β-galactosidase staining
PC3 cells were plated into a 96-well plate three 
days before fixing and staining the cells as outlined per 
the manufacturer’s protocol (Senescence β-galactosidase 
Staining Kit, Cell Signaling Technology #9860). Stained 
cells were imaged randomly in 5 locations from each well 
and the mean was the technical replicate. The mean of two 
technical replicates generated a biological replicate, and 
three biological replicates were used for each condition. 
Cell viability assay
Cell viability was measured using the MTT reagent 
(Calbiochem) and different doses of docetaxel. 5000 
cells were plated onto a 96-well tissue culture plate and 
incubated at 37 °C for 48 hours before drug treatment. 
Docetaxel was added from 0.001 nM to 100 nM and cells 
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were incubated for 72 hours at 37 °C. Media was removed 
from the cells and replaced with MTT reagent (5 mg/ml 
in PBS) for 4 hr. Absorbance was measured at 600 nm 
using a micro-plate reader ELx8200 (Biotek Instruments). 
Viability was the mean percentage of absorbance relative 
to an untreated well for three biological replicates. 
Gene set enrichment analysis (GSEA)
The desktop version 3.0 of GSEA was utilized 
along with datasets from the Molecular Signatures 
Database (MSigDB). A Gene Cluster Text file (.gct) was 
generated using the fpkm values for each of the three 
biological replicates in the RWPE-ERG and RWPE-ERG 
shELF1 conditions from the RNA-seq. The RWPE-ERG 
data represented the ELF1 Activated phenotype while 
the RWPE-ERG shELF1 data represented the ELF1 
Repressed phenotype in GSEA. The default parameters 
were used within GSEA except that the collapse dataset 
to gene symbols was set to False. A ranked file (.rnk) 
was generated from the prostate cancer TCGA dataset by 
determining the Pearson correlation between each gene 
and ELF1. The GSEAPreranked program determined 
enriched gene sets with the default parameters. 
Availability of data and materials
The next generation sequencing datasets supporting 
the conclusions of this article are available in the NCBI’s 
Gene Expression Omnibus (GEO) repository (http://www.
ncbi.nlm.nih.gov/geo/) accession number GSE113499. 
The RNA-sequencing data from patient tumor and adjacent 
normal samples were generated in whole by the TCGA 
Research Network (http://cancergenome.nih.gov/.). The 
RNA-sequencing data for various prostate cancer cell lines 
was obtained from a publicly available data set on GEO 
(GSE31728) [38]. The microarray data for patient samples 
with benign prostate tissue, localized prostate cancer, or 
metastatic castrate resistant prostate cancer is available on 
the NCBI’s GEO repository, accession number GSE35988 
[39]. The remaining datasets supporting the conclusions of 
this article are included within the article. 
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